莫沙必利联合质子泵抑制剂治疗胃食管反流病的Meta分析

发布时间：2018-02-14 06:11

本文关键词： 莫沙必利胃食管反流质子泵抑制剂随机对照试验 Meta分析　出处：《中国临床药理学杂志》2015年05期 　论文类型：期刊论文

【摘要】：目的评价莫沙必利治疗胃食管反流病(GERD)的有效性和安全性。方法检索Pub Med、EMBase、中国知网(CNKI)、中国生物医学文献数据库(CBM)、维普信息资源系统(VIP)、万方数据库,从建库至2013年6月,所有莫沙必利联合质子泵抑制剂(PPI)治疗胃食管反流病的随机对照试验。用Cochrane系统评价方法评价后,用Rev Man 5.2软件进行Meta分析。结果共纳入32项研究(2918例患者),治疗组(莫沙必利联合质子泵抑制剂)对GERD临床症状缓解率[OR=4.54,95%CI(3.59,5.75),P0.01]以及对内镜下胃食管炎症应答率[OR=4.37,95%CI(3.08,6.21),P0.01]均高于对照组(单用质子泵抑制剂)。治疗组不良反应发生数[OR=1.06,95%CI(0.74,1.53),P0.05],与对照组比较差异无统计学意义。结论试验组对胃食管反流病的治疗效果优于对照组,安全性与对照组差异无统计学意义。
[Abstract]:Objective to evaluate the efficacy and safety of mosapride in the treatment of gastroesophageal reflux disease (GERD). All randomized controlled trials of mosapride combined with proton pump inhibitor proton pump inhibitor in the treatment of gastroesophageal reflux disease. Rev Man 5.2 software was used to analyze Meta. Results in 32 studies, 2918 patients were enrolled in the study. The remission rate of clinical symptoms of GERD in the treatment group (mosapride combined with proton pump inhibitor) was higher than that in the treatment group [OR4.54% 95CIN 3.59 ~ 5.75 P0.01] and the gastroesophageal inflammation response rate (OR4.37 95CI3.086.21 / P0.01). The number of adverse reactions in the control group (treated with proton pump inhibitor alone) was not significantly different from that in the control group (P 0.05). Conclusion the therapeutic effect of the experimental group on gastroesophageal reflux disease is better than that of the control group. There was no significant difference in safety between the two groups.
【作者单位】：安徽医科大学第一附属医院药剂科;安徽医科大学公共卫生学院;
【基金】：“十二五”国家科技支撑计划课题“安全合理用药评价和干预技术研究与应用”(2013BAI06B04)
【分类号】：R571

【相似文献】